title: Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era.
abstract: Chronic myeloid leukemia (CML) management varies across Asia due to disparities in affluence and healthcare provision. We surveyed CML management practice at 33 hospitals in 14 countries/regions to identify treatment challenges and opportunities for harmonization. Patients were generally treated according to international guidelines; however, tyrosine kinase inhibitors (TKIs) and molecular monitoring are inaccessible to many patients not covered by national insurance or eligible for subsidized treatment. Late diagnosis and suboptimal monitoring, often due to cost and accessibility issues, are challenges. Priorities for Asia include: extending accessibility to TKIs; specialist laboratory monitoring; and enriching data to support regional CML management guidelines.
authors.affiliation: Division of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea. dwkim@catholic.ac.kr
authors.forename: Dong-Wook
authors.initials: DW
authors.lastname: Kim
authors.forename: Shripad D
authors.initials: SD
authors.lastname: Banavali
authors.forename: Udomsak
authors.initials: U
authors.lastname: Bunworasate
authors.forename: Yeow-Tee
authors.initials: YT
authors.lastname: Goh
authors.forename: Peter
authors.initials: P
authors.lastname: Ganly
authors.forename: He
authors.initials: H
authors.lastname: Huang
authors.forename: Ian
authors.initials: I
authors.lastname: Irving
authors.forename: Saengsuree
authors.initials: S
authors.lastname: Jootar
authors.forename: Hyun-Gyung
authors.initials: HG
authors.lastname: Goh
authors.forename: Liang-Piu
authors.initials: LP
authors.lastname: Koh
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Tomoki
authors.initials: T
authors.lastname: Naoe
authors.forename: Soo-Chin
authors.initials: SC
authors.lastname: Ng
authors.forename: Visalachy
authors.initials: V
authors.lastname: Purushotaman
authors.forename: Harryanto
authors.initials: H
authors.lastname: Reksodiputro
authors.forename: Lee-Yung
authors.initials: LY
authors.lastname: Shih
authors.forename: Jih-Luh
authors.initials: JL
authors.lastname: Tang
authors.forename: Arinobu
authors.initials: A
authors.lastname: Tojo
authors.forename: Jianmin
authors.initials: J
authors.lastname: Wang
authors.forename: Raymond
authors.initials: R
authors.lastname: Wong
mesh_terms: D001208:Asia; D003625:Data Collection; D057210:Delayed Diagnosis; D016503:Drug Delivery Systems; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000191:economics / Q000628:therapy*; D010139:Pacific Islands; D010346:Patient Care Management / Q000191:economics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
chemical_list: D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases